These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17098626)

  • 1. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers.
    Clarke PD; Adams P; Ibáñez R; Herzog C
    Travel Med Infect Dis; 2006 Dec; 4(6):313-8. PubMed ID: 17098626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1-16 years.
    Van Der Wielen M; Vertruyen A; Froesner G; Ibáñez R; Hunt M; Herzog C; Van Damme P
    Pediatr Infect Dis J; 2007 Aug; 26(8):705-10. PubMed ID: 17848882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
    Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epaxal: a virosomal vaccine to prevent hepatitis A infection.
    Bovier PA
    Expert Rev Vaccines; 2008 Oct; 7(8):1141-50. PubMed ID: 18844588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and tolerability of a paediatric presentation of a virosomal hepatitis A vaccine in Chilean children aged 1-16 years.
    Abarca K; Ibáñez I; de la Fuente P; Cerda L; Bergeret J; Frösner G; Ibarra H
    Vaccine; 2011 Nov; 29(48):8855-62. PubMed ID: 21983354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine.
    Beck BR; Hatz CF; Loutan L; Steffen R
    J Travel Med; 2004; 11(4):201-6. PubMed ID: 15541221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Serologic Follow-up of Children Vaccinated with a Pediatric Formulation of Virosomal Hepatitis A Vaccine Administered With Routine Childhood Vaccines at 12-15 Months of Age.
    Dagan R; Ashkenazi S; Livni G; Go O; Bagchi P; Sarnecki M
    Pediatr Infect Dis J; 2016 Jul; 35(7):e220-8. PubMed ID: 27093164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine.
    Bovier PA; Farinelli T; Loutan L
    Vaccine; 2005 Mar; 23(19):2424-9. PubMed ID: 15752828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients.
    Loutan L; Bovier P; Herzog C
    Vaccine; 2007 Aug; 25(34):6310-2. PubMed ID: 17640777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis A vaccine.
    Van Herck K; Hens A; De Coster I; Vertruyen A; Tolboom J; Sarnecki M; Van Damme P
    Pediatr Infect Dis J; 2015 Apr; 34(4):e85-91. PubMed ID: 25389920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the immunogenicity and safety of 3 inactivated hepatitis A vaccines in Korean children aged 12 to 18 months: An open-label, randomized, prospective, multicenter study.
    Hong SS; Choi UY; Ma SH; Lee SY; Han SB; Kim KH; Kang JH; Kim JH
    Medicine (Baltimore); 2019 Feb; 98(6):e14364. PubMed ID: 30732169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reappraisal of the Immunogenicity and Safety of Three Hepatitis A Vaccines in Adolescents.
    Yoon SH; Kim HW; Ahn JG; Kim IT; Kim JH; Kong KA; Kim KH
    J Korean Med Sci; 2016 Jan; 31(1):73-9. PubMed ID: 26770041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of a pediatric dose virosomal hepatitis A vaccine in Thai HIV-infected children.
    Saksawad R; Likitnukul S; Warachit B; Hanvivatvong O; Poovorawan Y; Puripokai P
    Vaccine; 2011 Jun; 29(29-30):4735-8. PubMed ID: 21570433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virosomal hepatitis a vaccine: comparing intradermal and subcutaneous with intramuscular administration.
    Frösner G; Steffen R; Herzog C
    J Travel Med; 2009; 16(6):413-9. PubMed ID: 19930383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seropositivity among Korean Young Adults Approximately 2 Years after a Single-Dose Vaccination against Hepatitis A Virus.
    Song YJ; Lim J; Park WS; Sohn H; Lee MS; Shin DH; Kim CB; Kim H; Oh GJ; Ki M
    PLoS One; 2015; 10(11):e0142297. PubMed ID: 26540392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine.
    Beck BR; Hatz C; Brönnimann R; Herzog C
    Clin Infect Dis; 2003 Nov; 37(9):e126-8. PubMed ID: 14557982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly.
    D'Acremont V; Herzog C; Genton B
    J Travel Med; 2006; 13(2):78-83. PubMed ID: 16553593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety and immunogenicity of a new inactivated hepatitis A vaccine].
    Ren A; Ma J; Feng F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Dec; 15(4):357-9. PubMed ID: 11986726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix.
    Connor BA; Phair J; Sack D; McEniry D; Hornick R; Banerjee D; Jensen E; Kuter B
    Clin Infect Dis; 2001 Feb; 32(3):396-401. PubMed ID: 11170947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.